ATR 蛋白抑制劑全球市場：臨床試驗和市場機會洞察 (2024)

Global ATR Protein Inhibitors Clinical Trials & Market Opportunity Insight 2024

出版日期: 2023年11月01日 | 出版商:

KuicK Research | 英文 88 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

ATR 激□的抑制已成為不斷發展的癌症藥物研究的一個有前途的途徑。 ATR 是一種絲胺酸/蘇胺酸蛋白激□，在細胞對 DNA 損傷的反應中發揮重要作用，從而保護基因組完整性。 ATR 失調與多種疾病有關，尤其是癌症，抑制 ATR 為利用癌細胞的脆弱性和提高現有治療的有效性提供了新的機會。目前，還沒有 ATR 蛋白抑制劑獲得監管部門的批准，但隨著開發管道中的幾個研究候選藥物進入 II 期試驗，這些新型抑制劑預計將受到更多關注。

ATR抑制的主要焦點是在腫瘤學領域。 ATR蛋白抑制劑有望增強損傷DNA的癌症治療的有效性，如化療和放療，並有望提高損傷DNA的癌症治療的有效性，如卵巢癌、膽管癌、乳腺癌、小細胞癌它是多種癌症類型聯合治療的候選藥物，包括晚期實體瘤和一些血液惡性腫瘤。在這些癌症中正在研究的 ATR 候選抑制劑包括 ATG-018、Elimusertib (BAY1895344)、Camonsertib (RP-3500) 和 Ceralasertib (AZD6738)，分別由 Antengene、Bayer、Repair Therapeutics 和 AstraZeneca 開發。這些候選藥物目前正處於臨床評估的各個階段。

與其他癌症治療方法相比，ATR 蛋白抑制劑具有多種優勢。如上所述，ATR 蛋白抑制劑有可能使癌細胞對常規治療敏感，從而減少所需劑量並減少副作用。儘管傳統療法很有效，但也有一些限制。 ATR 抑制有助於克服癌細胞對治療產生的抗藥性機制，進而改善患者的治療效果。此外，ATR 蛋白抑制劑透過針對患者特定的遺傳弱點，實現更個人化的癌症治療方法。在神經退化性疾病和病毒感染領域，ATR 抑制有望減緩或預防疾病進展並改善受影響個體的生活品質。

雖然 ATR 蛋白抑制劑的環境由於其優於現有治療方法而樂觀，但挑戰也存在，包括需要改進患者分類標準和更好地了解潛在的副作用。Masu。然而，ATR蛋白抑制劑的未來潛力是巨大的。隨著 ATR 蛋白抑制劑繼續展現出前景，它們在聯合療法中的應用預計將變得更加普遍，並有可能重塑癌症治療方案。此外，分子譜分析和基因檢測的進步可能使 ATR 的抑制更有針對性。

本報告調查了全球 ATR 蛋白抑制劑市場，並提供了市場概況，包括藥物趨勢、臨床試驗趨勢、區域趨勢以及進入市場的公司競爭格局。

Inhibition of the Ataxia telangiectasia and Rad3 related kinase, or ATR kinase, has emerged as a promising avenue in the ever evolving landscape of cancer pharmaceutical research. ATR is a serine/threonine-protein kinase that acts as a guardian of genomic integrity by playing a critical role in the cellular response to DNA damage. Dysregulation of ATR has been linked to various diseases, particularly cancer, and inhibiting ATR presents a novel opportunity to exploit the vulnerabilities of cancer cells and enhance the efficacy of existing therapies. No ATR inhibitors have received regulatory approval as of yet; however, with several investigational candidates in the development pipeline now entering phase II trials, these novel inhibitors are anticipated to gain more attention in the years to come.

The primary focus of ATR inhibition is in the realm of oncology. ATR inhibitors have shown promise in enhancing the effectiveness of DNA-damaging cancer therapies such as chemotherapy and radiation, making hem potential candidates for combination therapies in various cancer types such as ovarian cancer, bile duct carcinoma, breast carcinoma, small cell cancer and high grade neuroendocrine cancers among other advanced solid tumors, as well as some hematological malignancies. Some ATR-inhibiting candidates being investigated in these cancers are ATG-018, Elimusertib (BAY 1895344), Camonsertib (RP-3500), and Ceralasertib (AZD6738), which have been developed by Antengene, Bayer, Repare Therapeutics, and AstraZeneca, respectively. These candidates are now in various phases of clinical evaluation.

Recent research, however, has expanded the scope of ATR inhibitors to neurodegenerative diseases. ATR kinase has implications in maintaining neuronal genomic activity, making it a potential target for conditions like Parkinson's disease and Alzheimer's disease. Further studies are linking ATR with microbial infections, especially those caused by viruses. Along with ATM, or Ataxia-telangiectasia mutated kinase, ATR is exploited by viruses to facilitate viral replication and increase expression of viral proteins. In the case of HIV-1 and COVID-19, both of which have high infection and mortality rates, ATR inhibition has represented another promising prospect for the development of novel therapeutics to manage these diseases.

As a result, the pharmaceutical industry has invested significantly in the development of ATR inhibition, and several clinical trials are being conducted now to evaluate the efficacy of these candidates. VE-821, developed by Vertex Pharmaceuticals, was the first specific ATR inhibitor to be developed, which served as the blueprint for the development of VE-822, now licensed to Merck as Berzosertib. The drug further served as the foundation for M1774, a potent ATR inhibitor being studied by Merck in various solid cancers. Both Berzosertib and M1774 have demonstrated encouraging results in early phase clinical trials in combination with chemotherapy. Administration of these ATR inhibitors enhanced the sensitivity of cancer cells to DNA-damaging chemotherapies, which makes the elimination of cancer cells faster.

ATR inhibitors pose several benefits over other cancer therapies. As described above, ATR inhibitors sensitize cancer cells to conventional therapies, potentially reducing the required dosage and mitigating side effects. Conventional therapies are potent but also face several limitations, majorly resistance to treatment. ATR inhibition can help overcome resistance mechanisms that cancer cells development against treatment, therefore improving patient outcomes. Further, ATR inhibitors can also enable a more personalized approach to cancer treatment by targeting specific genetic vulnerabilities in patients. In the realm of neurodegenerative diseases and viral infections, ATR inhibition holds the promise of slowing or preventing disease progression and improving the quality of life of affected individuals.

Despite the optimism surrounding ATR inhibitors as outlined by their advantages over existing therapies, challenges exist such as the need for refined patient section criteria and a deeper understanding of the potential side effects. However, their future potential is vast. As ATR inhibitors continue to show promise, their integration into combination therapies is expected to become more common, potentially reshaping cancer treatment regimens. Moreover, advances in molecular profiling and genetic testing may enable a more targeted ATR inhibition.

The ongoing clinical and market trends for ATR inhibitors present a compelling narrative in the pharmaceutical domain. The novel approach to targeting DNA damage response pathways holds the promise of revolutionizing cancer treatment, as well as entering the treatment protocols for neurodegenerative and infectious diseases. With ongoing research studies revealing more about ATR kinase and its implications in different indications, it is understood the full potential of ATR inhibition is yet to be realized. As this happens, a new wave of development in the global pharmaceutical market is anticipated, which makes the ATR inhibition an exciting field.

1. Introduction to ATR Inhibition

1.1. Overview of ATR Protein & ATR Inhibition
1.2. History & Evolution of ATR Inhibitors

2. ATR Inhibitors: Research & Clinical Trials Overview by Indication

2.1. Solid Cancers
2.2. Hematological Cancers

3. Global ATR Inhibitors Market Outlook

3.1. Current Market Trends & Developments
3.2. Future Growth Avenues

4. ATR Inhibitors Development Trends by Region

4.1. US
4.2. EU
4.3. UK
4.4. Canada
4.5. China
4.6. Japan
4.7. Australia

5. Global ATR Protein Inhibitors Clinical Trials Overview

5.1. By Country
5.2. Indication
5.3. Phase
5.4. Therapy Class

6. Global ATR Protein Inhibitors Clinical Pipeline By Company, Indication & Phase

6.1. Research
6.2. Preclinical
6.3. Phase-I
6.4. Phase-I/II
6.5. Phase-II
6.6. Phase-III

7. Global ATR Inhibitors Market Drivers & Challenges

7.1. Drivers & Opportunities
7.2. Challenges & Restraints

8. Competitive Landscape

8.1. Antengene Corporation
8.2. Aprea
8.3. AstraZeneca
8.4. Bayer
8.5. Beijing Tide Pharmaceutical
8.6. Biocity Biopharmaceutics
8.7. Chipscreen Biosciences
8.8. IMPACT Therapeutics
8.9. Laevoroc Neuro-Oncology
8.10. Repare Therapeutics
8.11. Shanghai De Novo Pharmatech
8.12. Shanghai Junshi Biosciences
8.13. ShangPharma
8.14. Vertex Pharmaceuticals

簡介目錄圖表

List of Figures

Figure 1-1: ATR Mediated DNA Damage Repair Signaling
Figure 1-2: Benefits of ATR Inhibitors
Figure 1-3: ATR inhibitors in Clinical Trials
Figure 1-4: ATR Inhibitors - History & Evolution
Figure 2-1: LATIFY Phase III Study - Initiation & Completion Years
Figure 2-2: ATRiBRAVE Phase II Study - Initiation & Completion Years
Figure 2-3: DASH Phase II Study - Initiation & Completion Years
Figure 2-4: MATRiX Phase II Study - Initiation & Completion Years
Figure 2-5: NCI-2021-10751 Phase I/II Study - Initiation & Completion Years
Figure 2-6: ACE-CL-110 Phase I Study - Initiation & Completion Years
Figure 3-1: ATR inhibitors - Future Growth Avenues
Figure 5-1: Global - ATR Protein Inhibitors Clinical Trials by Country (Numbers), 2023 & 2024
Figure 5-2: Global - ATR Protein Inhibitors Clinical Trials by Indication (Numbers), 2023 & 2024
Figure 5-3: Global - ATR Protein Inhibitors Clinical Trials by Phase (Numbers), 2023 & 2024
Figure 5-4: Global - ATR Protein Inhibitors Clinical Trials by Therapy Class (Numbers), 2023 & 2024
Figure 7-1: ATR Inhibitors Market Drivers
Figure 7-2: ATR Inhibitors Market Challenges

List of Tables

Table 4-1: US - National Cancer Institute Sponsored Clinical Trials for ATR Inhibitors
Table 4-2: EU - Ongoing Clinical Trials for ATR Inhibitors
Table 4-3: UK - Ongoing Clinical Trials for ATR Inhibitors
Table 4-4: Canada - Ongoing Clinical Trials for ATR Inhibitors
Table 4-5: China - Ongoing Clinical Trials for ATR Inhibitors
Table 4-6: Japan - Ongoing Clinical Trials for ATR Inhibitor M1774
Table 4-7: Australia - Ongoing Clinical Trials for ATR Inhibitors

02-2729-4219

+886-2-2729-4219